investigation of melatonin in sleep quality in patients with cancer
Not Applicable
- Conditions
- sleep quality disorders.sleep disorders
- Registration Number
- IRCT2016051027840N1
- Lead Sponsor
- Vice chancellor for research, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
age between 16 to 80; Cancer patients who have trouble sleeping and chemotherapy have done for them and ended
Exclusion criteria: patients with underlying disorders and uncontrolled medical problems such as diabetes, hypertension, seizures; addiction and continuous use of sleep medications and anticoagulants and anticonvulsants; Individuals treated with anticoagulants and anticonvulsants and antidepressants and sleeping drugs
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sleep quality. Timepoint: Baseline,once a week for a amonth. Method of measurement: Based on pittsburgh sleep quality questionnaire.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie melatonin's effect on sleep quality in cancer patients with MT1/MT2 receptor expression?
How does melatonin compare to benzodiazepines in improving sleep efficiency for oncology patients with insomnia?
Are there specific circadian rhythm biomarkers that predict melatonin responsiveness in cancer-related sleep disorders?
What adverse events are associated with melatonin supplementation in cancer patients undergoing chemotherapy?
What combination therapies with melatonin show promise for treating sleep disturbances in breast cancer patients with tumor necrosis factor-alpha dysregulation?